Evidence map›Paper›PMID 40817818›Full record

ArticleStatistics in medicine2025

The Cox Model With Adaptive Fused Group Bridge Penalty to Incorporate Historical Data Into the Analysis of Clinical Trials With an Application to BMT CTN 1101.

Xi Fang, Soyoung Kim, Michael J Martens, Brent R Logan, Kwang Woo Ahn

Abstract read
In one paragraph

Article in Statistics in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xi FangDivision of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Soyoung KimDivision of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.ORCID https://orcid.org/0000-0003-1404-0575
Michael J MartensDivision of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Brent R LoganDivision of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Kwang Woo AhnDivision of Biostatistics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Blood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.U24HL138660 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Steven M. DeVine, Mehdi Hussain Hamadani · 2017 to 2026
$71.4M
Clinical and Translational Science AwardUL1TR001436 · NCATS · MEDICAL COLLEGE OF WISCONSIN · PI FREED, JULIE K · 2015 to 2025
$47.5M
Easy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8M
HRSA HHS HHSH234200637015CHRSA HHS HHSH250201200016CNCATS NIH HHS UL1 TR001436NCATS NIH HHS UL1TR001436NCI NIH HHS 4U10HL069294NCI NIH HHS 5U24CA076518NCI NIH HHS U24 CA076518NCI NIH HHS U24HL138660NHLBI NIH HHS U10 HL069294NHLBI NIH HHS U10HL069294NHLBI NIH HHS U24 HL138660Office of Naval Research N00014-16-1-2020Office of Naval Research N00014-17-1-2388
6 · The paper itself

Abstract

The incorporation of historical data (HD) into a clinical trial analysis can improve the precision and efficiency of treatment evaluation if the HD are exchangeable with clinical trial data. Evaluating the exchangeability of these two data sets is challenging, however, as an incorrect assessment of exchangeability yields invalid inference on the treatment effect that may produce bias and inflate the Type I error rate. To address this practical problem, we propose an adaptive fused group bridge penalty to evaluate the comparability of parameters between HD and clinical trial data and make inferences on the treatment effect. The proposed penalty has oracle properties, including consistency for identifying the underlying model and the asymptotic normality of the estimators. Simulation studies show that the proposed method controls the Type I error rate better and has higher power than competing methods under both exchangeable and non-exchangeable settings. We apply the proposed method by reanalyzing a Phase III trial while also leveraging a corresponding HD set.

Indexed as

Bone Marrow TransplantationClinical Trials as TopicClinical Trials, Phase III as TopicBiasComputer SimulationData Interpretation, StatisticalHumansProportional Hazards Modelsadaptive penaltyclinical trialsgroup bridgehistorical datasurvival data

Identifiers

PMID40817818
PMCPMC12614236

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.